TGFB1 and neuroendocrine neoplasm: In the later stages of the disease, the signaling between TGF-β and somatostatin is disrupted (somatostatin pathway is an antiproliferative pathway) forming an increased metastatic potential, in which TGF-β becomes an inducer rather than a suppressor of the transformation of neuroendocrine tumors [124,125].